Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BridgeBio Pharma, Inc.
  6. Summary
    BBIO   US10806X1028

BRIDGEBIO PHARMA, INC.

(BBIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
49.94(c) 49.9(c) 48.57(c) 50.44(c) 50.1 Last
675 406 2 348 956 861 425 601 630 857 232 Volume
-0.48% -0.08% -2.67% +3.85% -0.67% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 110 M - -
Net income 2021 -520 M - -
Net Debt 2021 177 M - -
P/E ratio 2021 -13,8x
Yield 2021 -
Sales 2022 132 M - -
Net income 2022 -528 M - -
Net Debt 2022 646 M - -
P/E ratio 2022 -14,0x
Yield 2022 -
Capitalization 7 503 M 7 503 M -
EV / Sales 2021 69,5x
EV / Sales 2022 61,5x
Nbr of Employees 391
Free-Float 65,2%
More Financials
Company
BridgeBio Pharma, Inc. is a United States-based company, The Company discovers and develops medicines that target well-characterized genetic diseases. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-561,... 
Read more
Sector
Pharmaceuticals
Calendar
10/04 | 04:30pmPresentation
More about the company
Ratings of BridgeBio Pharma, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about BRIDGEBIO PHARMA, INC.
09/20BRIDGEBIO PHARMA : Corporate Presentation September 2021
PU
09/15BRIDGEBIO PHARMA : Gets Fast Track Designation From FDA for Muscular Dystrophy Drug Candid..
MT
09/15BRIDGEBIO : Pharma Receives FDA Fast Track Designation for Investigational Therapy for the..
PR
09/15BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for th..
CI
09/15BridgeBio Gets FDA Fast-Track Designation for Limb-Girdle Muscular Dystrophy Type 2i Tr..
DJ
09/13BRIDGEBIO PHARMA : Corporate Presentation September 2021
PU
09/13NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/10BRIDGEBIO PHARMA : BofA Securities Upgrades BridgeBio Pharma to Buy From Neutral, Sets $75..
MT
09/09BRIDGEBIO PHARMA : Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
09/09BRIDGEBIO PHARMA : Corporate Presentation September 2021
PU
09/08BRIDGEBIO : Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR
08/25SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Wednesday
MT
08/25BRIDGEBIO PHARMA : LianBio Treat First Patient in Trial of Infigratinib for Gastric Cancer..
MT
08/25BRIDGEBIO PHARMA : and LianBio Announce First Patient Treated in Phase 2a Trial of Infigra..
BU
08/25LianBio and BridgeBio Pharma, Inc. Announce First Patient Treated in Phase 2a Trial of ..
CI
More news
News in other languages on BRIDGEBIO PHARMA, INC.

- No features available -

More news
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
More recommendations
Analysis
KKR earnings surge 63% on strong capital market business
Chart BRIDGEBIO PHARMA, INC.
Duration : Period :
BridgeBio Pharma, Inc. Technical Analysis Chart | BBIO | US10806X1028 | MarketScreener
Technical analysis trends BRIDGEBIO PHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 50,10 $
Average target price 79,67 $
Spread / Average Target 59,0%
EPS Revisions
Managers and Directors
Neil Kumar Chief Executive Officer & Director
Brian C. Stephenson Chief Financial Officer & Secretary
Uma Sinha Chief Scientific Officer
Richard H. Scheller Director, Chairman-Research & Development
Christine E. Siu Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BRIDGEBIO PHARMA, INC.-29.07%7 554
JOHNSON & JOHNSON3.45%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.18.36%244 283
NOVO NORDISK A/S48.08%227 557
ELI LILLY AND COMPANY31.25%205 250